Shahjada Selim
Associate Professor in Endocrinology.
Very keen in medical research especially in endocrinology & metabolism and NCDs.
Supervisors: Bangladesh Endocrine Society, AACE, ADA, APPES, ESE, EASD, BTS, BNCDF and IRB, BSMMU
Phone: +880 19 1900 0022
Address: Room#1520, Block#D, BSMMU, Shahbag, Dhaka, Bangladesh
Very keen in medical research especially in endocrinology & metabolism and NCDs.
Supervisors: Bangladesh Endocrine Society, AACE, ADA, APPES, ESE, EASD, BTS, BNCDF and IRB, BSMMU
Phone: +880 19 1900 0022
Address: Room#1520, Block#D, BSMMU, Shahbag, Dhaka, Bangladesh
less
Related Authors
Uploads
Papers by Shahjada Selim
variable clinical phenotypes defined by abnormal or excessive adiposity which
impairs physical and mental health. Although Bangladesh is experiencing a rise in
the prevalence of obesity, it is still undermanaged. The metabolic phenotype of the
people of our country is different from Caucasians. Therefore, there is an urgent
need for a structured, customized and evidence‑based clinical practice guideline
for the management of obesity in Bangladesh. Methodology: The Bangladesh
Endocrine Society (BES) Obesity Taskforce undertook to develop a position
statement for managing obesity in Bangladesh. The task force created a committee
of 19 members to write the statement based on international obesity guidelines,
randomized controlled trials, national observational studies, and expert opinion.
Several consultative meetings were arranged to discuss the position statement until
it was ratified unanimously by the committee. Results: The position statement
includes recommendations on the overall management of obesity. There are
sections on the diagnosis, assessment, treatment, and prevention of obesity in
adults of Bangladesh. Conclusion: This is a position statement for the people
of Bangladesh who are suffering from obesity. We hope it provides knowledge
to primary care physicians and endocrinologists to improve the assessment and
treatment of obesity. Through this position statement, BES hopes to improve the
management of obesity in Bangladesh and make it structured and uniform.
endocrine diseases, including conditions such as
hyperthyroidism, hypothyroidism, thyroid nodules, and
thyroid adenomas. In recent decades, the incidence of
these conditions has increased. Notably, cases of thyroid
cancer, particularly papillary thyroid carcinoma, have
risen modestly. Despite this increase, the mortality
rate for thyroid cancer remains low, potentially due
to overdiagnosis. Consequently, the decision between
immediate surgical intervention and active surveillance
for thyroid cancer treatment has become a prominent
topic of discussion.
once-daily basal insulins in subjects with type 2 diabetes (T2D) inadequately controlled with oral
anti-hyperglycemic drugs. This meta-analysis was conducted to address this knowledge gap.
Methods: Randomized controlled trials involving subjects with T2D inadequately controlled with oral
anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control
arm as add-on therapy were searched throughout the electronic databases. The primary outcome
assessed was the change from baseline in hemoglobin A1c (HbA1c).
Results: Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Compared to basal insulins, tirzepatide arms achieved greater reductions from the baseline in HbA1c
(tirzepatide 5 mg: mean difference (MD) 0.89% [95% CI: 1.23, 0.54]; tirzepatide 10 mg:
MD 1.11% [95% CI: 1.42, 0.79]; and tirzepatide 15 mg: MD 1.23% [95% CI: 1.48, 0.97];
P < .00001 for all). Additionally, the proportions of patients achieving HbA1c levels below 7.0%, 6.5%,
and 5.7% were signi cantly greater in the tirzepatide groups than in the basal insulin group. Greater
body weight and blood pressure reductions were observed with tirzepatide than with basal insulins.
Moreover, tirzepatide had a more favorable impact on lipid pro le. Hypoglycemia was less frequent
with tirzepatide. Gastrointestinal adverse events (AEs) were more frequent with tirzepatide (all
doses) than basal insulin, although serious AEs were comparable between the 2 groups.
Conclusion: Tirzepatide outperformed basal insulins in controlling blood glucose, body weight, blood
pressure, and lipids in subjects with T2D and is generally well-tolerated except for its higher
gastrointestinal AEs
autoantibodies (TSH Receptor Antibodies, or TRAbs), leading to unregulated thyroid hormone production. Diagnosis
is largely based on the typical clinical picture and laboratory thyroid panel. Establishment of elevated serum levels
of TRAbs by competitive binding assay or cell-binding assay has its unique role in diagnosis and management of GD,
especially in the differential diagnosis, therapy selection, prognostication, evaluation of thyroid function during preg-
nancy, peri-conceptional and neonatal thyroid workup, and in certain special situation. Inclusion of TRAbs in GD
diagnostic algorithm can improve cost-effectiveness of GD management. The current best practice guidelines were
developed to provide evidence-based recommendations in the use of TRABs in GD management for healthcare
providers in South Asia. A panel of endocrinologists with minimum 10 years of clinical experience in thyroid disorders
reviewed existing literature and their quality, and after deliberation and discussion, developed 21 recommendations
surrounding the best practices surrounding the role of TRAbs in GD management.
control of blood sugar among diabetic patients are not well described. We assessed the pattern of
diabetic care among ambulatory diabetic patients attending tertiary care hospitals in Bangladesh,
and explored the relationship of glycemic control with behavioral and metabolic risks. Any patient
18 years and older attending the medicine outpatient department (OPD) at randomly selected
three government tertiary hospitals in three divisions in Bangladesh were examined by hospital
doctors. If a patient who was diagnosed as having diabetes and produced any medical document
to support the diagnosis was recruited following an informed consent. Data on socio-demographic
characteristics, diabetic care plan and behavioral risks, including tobacco use, physical activity,
healthy diet (daily fruits and vegetable consumption) and salt intake were obtained from study
participants by recall. Three milliliters of venous blood were tested to determine uncontrolled
diabetes by measuring glycated hemoglobin (HbA1C
>
7.0), and hyperlipidemia by measuring total
cholesterol (> 200 mg/dL), high density lipoprotein/HDL (< 40 Mg/dL, low density lipoprotein/ LDL
(> 200 mg/dL), and Triglyceride (> 160 mg/dL). A Total of 465 patients were enrolled. The Mean age
was 49 years (SD:11) and 58% were women. Sixty percent patients were on a treatment plan of
anti-diabetic drugs (drug), healthy diet (diet) and physical activity (PA), 13.3% diet and drug, 9.7% on
drug only, 6.4% on diet and PA, 3.9% on PA and drug, 1.3% on PA only and 0.9% on diet only. Two-
third of the patients (68.6%) had uncontrolled diabetes, which was three times higher, if a patient
had diabetes for more than five years than otherwise (OR: 3.31, 95% CI 2.06–5.33), two times higher
if a patient did not consume fruits (OR: 2.28, 1.34–3.87), or three times higher, if a patient did not
consume vegetables (OR: 3.70, 95% CI 1.80–7.59) than otherwise, 78% higher, if a patient had taken
extra salt in meal than otherwise (OR: 1.78, 95% CI 1.13–2.80) and nine times higher, if a patient had
a raised total cholesterol level (> 200 mg/dL) than otherwise (OR: 9.60, 95% CI 2.60–35.40) and three
times higher, if a patient had a raised LDL level compared than otherwise (OR: 3.33, 95% CI: 1.93-
5.70). Diabetic patients seeking care at tertiary hospitals in Bangladesh follow diverse diabetic care
plans and the majority of them do not have diabetes under control. Unhealthy dietary practice and hyperlipidemia among diabetic patients contribute to uncontrolled diabetes. Routine monitoring of blood glucose and enforcing lifestyle modifications could promote effective control of diabetes among
diabetic patients in Bangladesh.
were reported to be associated with malignant thyroid nodules. This study aimed to assess the diagnostic accuracy of serum
thyroid autoantibody levels for malignant thyroid nodules.
Methods: From March 2023 to January 2024, we recruited 104 consecutive patients with thyroid nodules confirmed by ultra-
sonography in three departments of Bangabandhu Sheikh Mujib Medical University. Out of these, 52 were diagnosed with
malignant thyroid nodules using fine needle aspiration cytology, while the remaining 52 had benign thyroid nodules. Serum
thyroid autoantibodies were measured using the immunoassay technique.
Results: The mean levels of serum thyroid peroxidase antibody (TPOAb) were significantly higher (P<0.001) in the malignant
group compared to the benign group (36.1 versus 24.0 IU/mL). The mean levels of serum thyroglobulin antibodies (TgAb)
were also significantly higher (P<0.001) in the malignant group (39.8 IU/mL versus 29.1 IU/mL). Elevated TPOAb (>40 IU/mL)
and TgAb (>35 IU/mL) showed reasonable accuracy (60% to 65%) in detecting malignancy of thyroid nodules.
Conclusions: Thyroid malignancy is positively associated with TgAb and TPOAb. Therefore, thyroid autoantibodies could be
considered for screening malignancy in thyroid nodules.
At Colombo, the South Asian Obesity Federation (SOF) declares its
commitment to a comprehensive person-centered, public-inclusive,
policy-concordant campaign against obesity. The SOF commits
to conducting academic/research activities, awareness campaigns,
advocacy efforts, and audit of obesity related activities across the South
Asian region. The SOF plans to tackle obesity as an individual, family,
community, and national level, through health promotive, preventive,
medical and surgical strategies
Article Details
variable clinical phenotypes defined by abnormal or excessive adiposity which
impairs physical and mental health. Although Bangladesh is experiencing a rise in
the prevalence of obesity, it is still undermanaged. The metabolic phenotype of the
people of our country is different from Caucasians. Therefore, there is an urgent
need for a structured, customized and evidence‑based clinical practice guideline
for the management of obesity in Bangladesh. Methodology: The Bangladesh
Endocrine Society (BES) Obesity Taskforce undertook to develop a position
statement for managing obesity in Bangladesh. The task force created a committee
of 19 members to write the statement based on international obesity guidelines,
randomized controlled trials, national observational studies, and expert opinion.
Several consultative meetings were arranged to discuss the position statement until
it was ratified unanimously by the committee. Results: The position statement
includes recommendations on the overall management of obesity. There are
sections on the diagnosis, assessment, treatment, and prevention of obesity in
adults of Bangladesh. Conclusion: This is a position statement for the people
of Bangladesh who are suffering from obesity. We hope it provides knowledge
to primary care physicians and endocrinologists to improve the assessment and
treatment of obesity. Through this position statement, BES hopes to improve the
management of obesity in Bangladesh and make it structured and uniform.
endocrine diseases, including conditions such as
hyperthyroidism, hypothyroidism, thyroid nodules, and
thyroid adenomas. In recent decades, the incidence of
these conditions has increased. Notably, cases of thyroid
cancer, particularly papillary thyroid carcinoma, have
risen modestly. Despite this increase, the mortality
rate for thyroid cancer remains low, potentially due
to overdiagnosis. Consequently, the decision between
immediate surgical intervention and active surveillance
for thyroid cancer treatment has become a prominent
topic of discussion.
once-daily basal insulins in subjects with type 2 diabetes (T2D) inadequately controlled with oral
anti-hyperglycemic drugs. This meta-analysis was conducted to address this knowledge gap.
Methods: Randomized controlled trials involving subjects with T2D inadequately controlled with oral
anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control
arm as add-on therapy were searched throughout the electronic databases. The primary outcome
assessed was the change from baseline in hemoglobin A1c (HbA1c).
Results: Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Compared to basal insulins, tirzepatide arms achieved greater reductions from the baseline in HbA1c
(tirzepatide 5 mg: mean difference (MD) 0.89% [95% CI: 1.23, 0.54]; tirzepatide 10 mg:
MD 1.11% [95% CI: 1.42, 0.79]; and tirzepatide 15 mg: MD 1.23% [95% CI: 1.48, 0.97];
P < .00001 for all). Additionally, the proportions of patients achieving HbA1c levels below 7.0%, 6.5%,
and 5.7% were signi cantly greater in the tirzepatide groups than in the basal insulin group. Greater
body weight and blood pressure reductions were observed with tirzepatide than with basal insulins.
Moreover, tirzepatide had a more favorable impact on lipid pro le. Hypoglycemia was less frequent
with tirzepatide. Gastrointestinal adverse events (AEs) were more frequent with tirzepatide (all
doses) than basal insulin, although serious AEs were comparable between the 2 groups.
Conclusion: Tirzepatide outperformed basal insulins in controlling blood glucose, body weight, blood
pressure, and lipids in subjects with T2D and is generally well-tolerated except for its higher
gastrointestinal AEs
autoantibodies (TSH Receptor Antibodies, or TRAbs), leading to unregulated thyroid hormone production. Diagnosis
is largely based on the typical clinical picture and laboratory thyroid panel. Establishment of elevated serum levels
of TRAbs by competitive binding assay or cell-binding assay has its unique role in diagnosis and management of GD,
especially in the differential diagnosis, therapy selection, prognostication, evaluation of thyroid function during preg-
nancy, peri-conceptional and neonatal thyroid workup, and in certain special situation. Inclusion of TRAbs in GD
diagnostic algorithm can improve cost-effectiveness of GD management. The current best practice guidelines were
developed to provide evidence-based recommendations in the use of TRABs in GD management for healthcare
providers in South Asia. A panel of endocrinologists with minimum 10 years of clinical experience in thyroid disorders
reviewed existing literature and their quality, and after deliberation and discussion, developed 21 recommendations
surrounding the best practices surrounding the role of TRAbs in GD management.
control of blood sugar among diabetic patients are not well described. We assessed the pattern of
diabetic care among ambulatory diabetic patients attending tertiary care hospitals in Bangladesh,
and explored the relationship of glycemic control with behavioral and metabolic risks. Any patient
18 years and older attending the medicine outpatient department (OPD) at randomly selected
three government tertiary hospitals in three divisions in Bangladesh were examined by hospital
doctors. If a patient who was diagnosed as having diabetes and produced any medical document
to support the diagnosis was recruited following an informed consent. Data on socio-demographic
characteristics, diabetic care plan and behavioral risks, including tobacco use, physical activity,
healthy diet (daily fruits and vegetable consumption) and salt intake were obtained from study
participants by recall. Three milliliters of venous blood were tested to determine uncontrolled
diabetes by measuring glycated hemoglobin (HbA1C
>
7.0), and hyperlipidemia by measuring total
cholesterol (> 200 mg/dL), high density lipoprotein/HDL (< 40 Mg/dL, low density lipoprotein/ LDL
(> 200 mg/dL), and Triglyceride (> 160 mg/dL). A Total of 465 patients were enrolled. The Mean age
was 49 years (SD:11) and 58% were women. Sixty percent patients were on a treatment plan of
anti-diabetic drugs (drug), healthy diet (diet) and physical activity (PA), 13.3% diet and drug, 9.7% on
drug only, 6.4% on diet and PA, 3.9% on PA and drug, 1.3% on PA only and 0.9% on diet only. Two-
third of the patients (68.6%) had uncontrolled diabetes, which was three times higher, if a patient
had diabetes for more than five years than otherwise (OR: 3.31, 95% CI 2.06–5.33), two times higher
if a patient did not consume fruits (OR: 2.28, 1.34–3.87), or three times higher, if a patient did not
consume vegetables (OR: 3.70, 95% CI 1.80–7.59) than otherwise, 78% higher, if a patient had taken
extra salt in meal than otherwise (OR: 1.78, 95% CI 1.13–2.80) and nine times higher, if a patient had
a raised total cholesterol level (> 200 mg/dL) than otherwise (OR: 9.60, 95% CI 2.60–35.40) and three
times higher, if a patient had a raised LDL level compared than otherwise (OR: 3.33, 95% CI: 1.93-
5.70). Diabetic patients seeking care at tertiary hospitals in Bangladesh follow diverse diabetic care
plans and the majority of them do not have diabetes under control. Unhealthy dietary practice and hyperlipidemia among diabetic patients contribute to uncontrolled diabetes. Routine monitoring of blood glucose and enforcing lifestyle modifications could promote effective control of diabetes among
diabetic patients in Bangladesh.
were reported to be associated with malignant thyroid nodules. This study aimed to assess the diagnostic accuracy of serum
thyroid autoantibody levels for malignant thyroid nodules.
Methods: From March 2023 to January 2024, we recruited 104 consecutive patients with thyroid nodules confirmed by ultra-
sonography in three departments of Bangabandhu Sheikh Mujib Medical University. Out of these, 52 were diagnosed with
malignant thyroid nodules using fine needle aspiration cytology, while the remaining 52 had benign thyroid nodules. Serum
thyroid autoantibodies were measured using the immunoassay technique.
Results: The mean levels of serum thyroid peroxidase antibody (TPOAb) were significantly higher (P<0.001) in the malignant
group compared to the benign group (36.1 versus 24.0 IU/mL). The mean levels of serum thyroglobulin antibodies (TgAb)
were also significantly higher (P<0.001) in the malignant group (39.8 IU/mL versus 29.1 IU/mL). Elevated TPOAb (>40 IU/mL)
and TgAb (>35 IU/mL) showed reasonable accuracy (60% to 65%) in detecting malignancy of thyroid nodules.
Conclusions: Thyroid malignancy is positively associated with TgAb and TPOAb. Therefore, thyroid autoantibodies could be
considered for screening malignancy in thyroid nodules.
At Colombo, the South Asian Obesity Federation (SOF) declares its
commitment to a comprehensive person-centered, public-inclusive,
policy-concordant campaign against obesity. The SOF commits
to conducting academic/research activities, awareness campaigns,
advocacy efforts, and audit of obesity related activities across the South
Asian region. The SOF plans to tackle obesity as an individual, family,
community, and national level, through health promotive, preventive,
medical and surgical strategies
Article Details